IFNG and colorectal carcinoma: A combination of IFN-γ ELISPOT assays and proliferation assays to monitor responses to the recall antigens PPD and HA, demonstrated equally robust responses in CRC patients and healthy controls, indicating that immune responses to non-tumor antigens are unimpaired in CRC patients.